Morsa Images On July 9th, uniQure N.V. (NASDAQ:QURE) announced 24-month trial data for its Phase 1/2 clinical trials for AMT-130, an investigational gene therapy for Huntington’s Disease. Despite only enrolling 29 patients in the trial and having data for only 9 at the high dosage, the reduction of disease progression of 80% was so great that it was still statistically significant. The market obviously liked this news, as the two trading days following its release saw QURE move from $3.78 to $10.12. I b ...